Sol-Gel Technologies Ltd.

NASDAQ:SLGL

Biotechnology

Healthcare
$53.36 +1.69%

+$1.19 today

Market cap
$174.70M
Beta
1.13
P/E (TTM)
-194.1
EPS (TTM)
-$0.37
52W Low $6.96High $97.97

Volume 0.03M

Average 0.04M

SLGL Debt Repayment

Cash used to repay borrowings during the period.

Sol-Gel Technologies Ltd.NASDAQ: SLGL

Debt Repayment · Q2 FY2024 · quarter ended Jun 2024

Debt repayment outflow grows to $0

Q2 FY2024 debt repayment was $0, compared with $0 a year earlier. Trailing-twelve-month debt repayment was $0.

Context

  • Debt repayment amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Debt repayment increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly debt repayment holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2024
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMJun 2024
$0— YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Debt Repayment vs competitors

How SLGL compares with its peers on the latest reported figures

  • SLGL's LTM Jun 2024 debt repayment of $0 is the 5th largest of the 10 companies compared; the peer median is $0.
  • Debt repayment amounts to 0.0% of revenue for SLGL, versus a peer median of 0.0%.
SLGL Competitors Peer median
Debt Repayment for SLGL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PLRXPliant Therapeutics, Inc.LTM Mar 2026$32.27M -3226800.0%——
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$10.36M -66.1%——
OKYOOKYO Pharma LimitedFY2025$950K ———
CLNNClene Inc.LTM Mar 2026$90K -99.2%-41.4%67.2%
SLGLSol-Gel Technologies Ltd.LTM Jun 2024$0 ——0.0%
OVIDOvid Therapeutics Inc.LTM Mar 2026$0 ——0.0%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$0 ———
MGNXMacroGenics, Inc.LTM Mar 2026$0 ——0.0%
COYACoya Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
TLSATiziana Life Sciences LtdFY2025$0 +100.0%——
Peer median (excluding SLGL) $0-82.6%-41.4%0.0%

Competitors are the stored peer set for SLGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income3.22M(14.92M)(27.24M)(10.58M)(6.13M)
Depreciation & Amortization880K562K342K233K109K
Deferred Income Tax(96K)0000
Stock-Based Compensation687K1.53M1.86M786K0
Change in Working Capital(12.44M)3.54M7.67M(4.4M)6.19M
Accounts Receivables(18.31M)12.55M7.54M(4.2M)1.63M
Inventory00000
Accounts Payables5.62M(8.3M)1.47M780K820K
Other Working Capital274K(709K)(1.34M)(981K)3.75M
Other Non-Cash Items55K(188K)(361K)74K148K
Operating Cash Flow(7.69M)(9.48M)(17.73M)(13.89M)322K
Capital Expenditures(143K)(171K)(134K)(2K)(47K)
Acquisitions (Net)000054K
Purchases of Investments(6.76M)(10.01M)(23.98M)0(14.08M)
Sales of Investments26.78M11.88M14.3M26.69M5.51M
Other Investing Activities(5K)074K6K(20K)
Investing Cash Flow19.87M1.7M(9.74M)26.69M(8.58M)
Debt Repayment00000
Common Stock Issued505K15K21.54M06K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities332K0268K00
Financing Cash Flow837K15K21.81M06K
Effect of Forex Changes(55K)133K(73K)(1K)(204K)
Net Change in Cash12.96M(7.64M)(5.74M)12.8M(8.46M)
Free Cash Flow(7.83M)(9.66M)(17.86M)(13.89M)275K

Sol-Gel Technologies Ltd.

NASDAQ:SLGL

Intrinsic Alpha fair value

Locked

Current Price

$53.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.